Prospective collection of data of possible prognostic relevance in patients with indolent non - follicular B-CELL Lymphomas.
The present study is designed as a prospective collection of information potentially useful to predict the prognosis of newly diagnosed patients with non-follicular low grade B-cell lymphoma. The study is aimed to verify whether a prognostic collection of data would allow the development of a more accurate prognostic assessment for non-follicular low grade B-cell lymphomas.
Study Type
OBSERVATIONAL
Enrollment
370
Patients registered in the study despite their planned treatment, watch and wait policy included. The "planned treatment" mentioned in the protocol is just the ideal approach proposed by investigators.The treatment can change depending on the evolution of the disease, without this affects the study's purposes.
Progression-free survival for the treated cohort
Progression free survival (PFS) will be measured from the date of randomization to the date of documented first occurrence of disease progression or relapse or to the date of death from any cause. Patients who are lost to follow up will be censored at their last assessment date.
Time frame: September 2024 (13 years)
Progression-free survival for the untreated cohort
Progression free survival (PFS) will be measured from the date of randomization to the date of documented first occurrence of disease progression or relapse or to the date of death from any cause. Patients who are lost to follow up will be censored at their last assessment date.
Time frame: September 2024 (13 years)
Overall survival
Overall survival (OS) is defined as the time from the study entry until the date of death irrespective of cause. Patients who have not died at the time of end of the whole study , and patients who are lost to follow up , will be censored at the date of the last contact.
Time frame: September 2024 (13 years)
Event-free survival
Event Free Survival (EFS) is measured from the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression) or death from any cause.
Time frame: September 2024 (13 years)
Remission rate with initial therapy
Remission rate (RR) is defined as the number of complete and partial remission (CR and PR) after the completion of the first line of treatment.
Time frame: September 2017 (Six years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Vienna Univ Med Int I
Vienna, Austria
Center of Hematology and Hemotherapy, UNICAMP, University of Campinas
Campinas, Brazil
Universidade Federal Do Rio de Janeiro
Rio de Janeiro, Brazil
São Paulo-Santa Casa Medical School
São Paulo, Brazil
Hospital Saint-Louis
Paris, France
UO Oncoematologia Ospedale Umberto I
Pagani, Salerno, Italy
Oncologia Medica A - Centro di Riferimento Oncologico
Aviano (PN), Italy
UO Ematologia con Trapianto Policlinico Consorziale
Bari, Italy
USC Ematologia Ospedali Riuniti di Bergamo
Bergamo, Italy
Ematologia e CTMO Ospedale Businco
Cagliari, Italy
...and 36 more locations
Epidemiology
Will be collected the risk factors potentially associated to the outcome of indolent non follicular lymphomas (clinical status, biochemistry, hemochrome, HCV, HBV and autoimmnity markers). Will be collected the risk factors potentially associated to the outcome of indolent non follicular lymphoma (clinical status, biochemistry, hemochrome, HCV, HBV and autoimmunity markers). Those risk factors will be utilized to obtain a prognostic model (prognostic index) from the Cox proportional hazard regression and, finally, a prognostic score grouping the prognostic index in at least three group of risk (low, intermediate, high risk).
Time frame: September 2016 (Five years)
Time dependent analysis for patients in Watch & Wait policy.
In WW group the start of treatment will be treated as a time-varying covariate in Cox proportional hazard regression.
Time frame: September 2024 (13 years)
Remission rates with second and subsequent lines of therapy
Remission rate (RR) is defined as the number of CR and PR after the second and subsequent lines of therapy, due to progression disease.
Time frame: September 2024 (13 years)